Vis enkel innførsel

dc.contributor.authorValla, Marit
dc.contributor.authorEngstrøm, Monica J
dc.contributor.authorYtterhus, Borgny
dc.contributor.authorHansen, Åse Kristin Skain
dc.contributor.authorAkslen, Lars A.
dc.contributor.authorVatten, Lars Johan
dc.contributor.authorOpdahl, Signe
dc.contributor.authorBofin, Anna M.
dc.date.accessioned2018-01-19T12:29:07Z
dc.date.available2018-01-19T12:29:07Z
dc.date.created2017-03-16T14:17:32Z
dc.date.issued2017
dc.identifier.citationBreast Cancer Research and Treatment. 2017, 162 (2), 243-253.nb_NO
dc.identifier.issn0167-6806
dc.identifier.urihttp://hdl.handle.net/11250/2478365
dc.description.abstractPurpose Proliferation is a hallmark of cancer. Using a combined genomic approach, FGD5 amplification has been identified as a driver of proliferation in Luminal breast cancer. We aimed to describe FGD5 copy number change in breast cancer, and to assess a possible association with tumour proliferation and prognosis. Methods We used fluorescence in situ hybridization targeting FGD5 and chromosome 3 centromere (CEP3) on formalin-fixed, paraffin-embedded tissue from 430 primary breast cancers and 108 lymph node metastases, from a cohort of Norwegian breast cancer patients. We tested the association between FGD5 copy number status and proliferation (assessed by Ki67 levels and mitotic count) using Pearson’s Chi square test, and assessed the prognostic impact of FGD5 copy number change by estimating cumulative risks of death and hazard ratios. Results We identified FGD5 amplification (defined as FGD5/CEP3 ratio ≥2 or mean FGD5/tumour cell ≥4) in 9.5% of tumours. Mitotic count and Ki67 levels were higher in tumours with FGD5 copy number increase, compared to tumours with no copy number change. After 10 years of follow-up, cumulative risk of death from breast cancer was higher among cases with FGD5 amplification [48.1% (95% CI 33.8–64.7)], compared to non-amplified cases [27.7% (95% CI 23.4–32.6)]. Conclusions FGD5 is a new prognostic marker in breast cancer, and increased copy number is associated with higher tumour proliferation and poorer long-term prognosis.nb_NO
dc.language.isoengnb_NO
dc.publisherSpringer Verlagnb_NO
dc.titleFGD5 amplification in breast cancer patients is associated with tumor proliferation and a poorer prognosisnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber243-253nb_NO
dc.source.volume162nb_NO
dc.source.journalBreast Cancer Research and Treatmentnb_NO
dc.source.issue2nb_NO
dc.identifier.doi10.1007/s10549-017-4125-8
dc.identifier.cristin1458808
dc.description.localcodeThis is a post-peer-review, pre-copyedit version of an article published in [Breast Cancer Research and Treatment]. Locked until 25.1.2019 due to copyright restrictions. The final authenticated version is available online at: https://link.springer.com/article/10.1007%2Fs10549-017-4125-8nb_NO
cristin.unitcode194,65,20,0
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for samfunnsmedisin og sykepleie
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel